Literature DB >> 15245610

Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow.

Rebecca L Elstrom1, Donald E Tsai, Jo-Anne Vergilio, Lisa H Downs, Abass Alavi, Stephen J Schuster.   

Abstract

[18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) is increasingly used for the clinical staging of lymphomas and for assessment of response to therapy. We report the case of a woman with classic Hodgkin's lymphoma who had marked FDG uptake by tumor and bone marrow suggestive of diffuse marrow involvement by lymphoma. However, iliac crest bone marrow examination showed marked myeloid hyperplasia without evidence of lymphoma involvement. We discuss the implications for interpretation of FDG-PET imaging of bone marrow in lymphomas.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15245610     DOI： 10.3816/clm.2004.n.012

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN： 1526-9655


  10 in total

Review 1.  FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Thomas C Kwee; Bart de Keizer; Rob Fijnheer; John M H de Klerk; Rutger A J Nievelstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-27       Impact factor: 9.236

2.  Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma.

Authors:  Ingeborg Goethals; Pieter Hoste; Ciel De Vriendt; Peter Smeets; Joris Verlooy; Hamphrey Ham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

3.  Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow.

Authors:  Toshiki Kazama; Nancy Swanston; Donald A Podoloff; Homer A Macapinlac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

4.  FDG-PET scans in patients with lymphoma.

Authors:  Rebecca L Elstrom; John P Leonard
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

5.  18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin's lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement.

Authors:  Aamna Hassan; Maimoona Siddique; Humayun Bashir; Saima Riaz; Rabia Wali; Asma Mahreen; M Khalid Nawaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-22       Impact factor: 9.236

6.  Distinguishing imaging features between spinal hyperplastic hematopoietic bone marrow and bone metastasis.

Authors:  Y Shigematsu; T Hirai; K Kawanaka; S Shiraishi; M Yoshida; M Kitajima; H Uetani; M Azuma; Y Iryo; Y Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-19       Impact factor: 3.825

7.  A predicting model of bone marrow malignant infiltration in 18F-FDG PET/CT images with increased diffuse bone marrow FDG uptake.

Authors:  Mingge Zhou; Yumei Chen; Jianjun Liu; Gang Huang
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

8.  Prognostic Value of Bone Marrow FDG Uptake Pattern of PET/CT in Newly Diagnosed Diffuse Large B-cell Lymphoma.

Authors:  Yumei Chen; Mingge Zhou; Jianjun Liu; Gang Huang
Journal:  J Cancer       Date:  2018-03-14       Impact factor: 4.207

9.  Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.

Authors:  Chin-Chuan Chang; Shih-Feng Cho; Hung-Pin Tu; Chia-Yang Lin; Ya-Wen Chuang; Shu-Min Chang; Wen-Ling Hsu; Ying-Fong Huang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

10.  Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma.

Authors:  H Tahsin Özpolat; Ebru Yilmaz; Hasan Sami Goksoy; Sahre Özpolat; Öner Dogan; Seher Nilgun Unal; Meliha Nalcaci
Journal:  Blood Res       Date:  2018-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.